JP2014520852A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520852A5
JP2014520852A5 JP2014520273A JP2014520273A JP2014520852A5 JP 2014520852 A5 JP2014520852 A5 JP 2014520852A5 JP 2014520273 A JP2014520273 A JP 2014520273A JP 2014520273 A JP2014520273 A JP 2014520273A JP 2014520852 A5 JP2014520852 A5 JP 2014520852A5
Authority
JP
Japan
Prior art keywords
buffer composition
norovirus
genogroup
buffer
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014520273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520852A (ja
JP6208659B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/046222 external-priority patent/WO2013009849A1/en
Publication of JP2014520852A publication Critical patent/JP2014520852A/ja
Publication of JP2014520852A5 publication Critical patent/JP2014520852A5/ja
Application granted granted Critical
Publication of JP6208659B2 publication Critical patent/JP6208659B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014520273A 2011-07-11 2012-07-11 非経口ノロウイルスワクチン製剤 Active JP6208659B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11
US61/506,447 2011-07-11
PCT/US2012/046222 WO2013009849A1 (en) 2011-07-11 2012-07-11 Parenteral norovirus vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017091755A Division JP6613259B2 (ja) 2011-07-11 2017-05-02 非経口ノロウイルスワクチン製剤

Publications (3)

Publication Number Publication Date
JP2014520852A JP2014520852A (ja) 2014-08-25
JP2014520852A5 true JP2014520852A5 (cg-RX-API-DMAC7.html) 2015-09-03
JP6208659B2 JP6208659B2 (ja) 2017-10-04

Family

ID=47506489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014520273A Active JP6208659B2 (ja) 2011-07-11 2012-07-11 非経口ノロウイルスワクチン製剤
JP2017091755A Active JP6613259B2 (ja) 2011-07-11 2017-05-02 非経口ノロウイルスワクチン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017091755A Active JP6613259B2 (ja) 2011-07-11 2017-05-02 非経口ノロウイルスワクチン製剤

Country Status (29)

Country Link
US (5) US9801934B2 (cg-RX-API-DMAC7.html)
EP (3) EP2731621B1 (cg-RX-API-DMAC7.html)
JP (2) JP6208659B2 (cg-RX-API-DMAC7.html)
KR (1) KR102096937B1 (cg-RX-API-DMAC7.html)
CN (3) CN105031637A (cg-RX-API-DMAC7.html)
AU (2) AU2012282658B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014000656A2 (cg-RX-API-DMAC7.html)
CA (1) CA2841356C (cg-RX-API-DMAC7.html)
CL (1) CL2014000082A1 (cg-RX-API-DMAC7.html)
CR (2) CR20190540A (cg-RX-API-DMAC7.html)
DK (1) DK3299030T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2014000004A (cg-RX-API-DMAC7.html)
EA (3) EA202090699A3 (cg-RX-API-DMAC7.html)
EC (1) ECSP14013201A (cg-RX-API-DMAC7.html)
ES (2) ES2926487T3 (cg-RX-API-DMAC7.html)
GE (1) GEP201706668B (cg-RX-API-DMAC7.html)
HK (2) HK1199202A1 (cg-RX-API-DMAC7.html)
IL (1) IL230356B (cg-RX-API-DMAC7.html)
MA (1) MA35414B1 (cg-RX-API-DMAC7.html)
MX (2) MX356586B (cg-RX-API-DMAC7.html)
MY (1) MY170746A (cg-RX-API-DMAC7.html)
PE (1) PE20140845A1 (cg-RX-API-DMAC7.html)
PH (3) PH12021551773A1 (cg-RX-API-DMAC7.html)
PL (2) PL2731621T3 (cg-RX-API-DMAC7.html)
SG (1) SG10201605644WA (cg-RX-API-DMAC7.html)
TN (1) TN2014000008A1 (cg-RX-API-DMAC7.html)
UA (1) UA117732C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013009849A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201401012B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2601970B1 (en) 2006-09-29 2016-10-26 Takeda Vaccines, Inc. Norovirus vaccine formulations
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
BR112014000656A2 (pt) 2011-07-11 2017-02-14 Takeda Vaccines Inc formulações de vacina parenteral contra norovírus
EP3052631B1 (en) 2013-10-03 2019-08-07 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
JP6556632B2 (ja) 2013-12-16 2019-08-07 武田薬品工業株式会社 マイクロニードル
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
AU2018269319A1 (en) * 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2019158653A1 (en) * 2018-02-15 2019-08-22 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
US20210121511A1 (en) * 2018-05-29 2021-04-29 Unm Rainforest Innovations Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP4087604A4 (en) * 2020-01-08 2023-11-01 Bharat Biotech International Limited COMPOSITIONS OF VIRAL VACCINES AND THEIR PREPARATION METHODS
JPWO2022210742A1 (cg-RX-API-DMAC7.html) 2021-03-29 2022-10-06
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant
WO2025077799A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Method of preparing norovirus vaccine without adjuvant

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
AU1893592A (en) 1991-03-25 1992-10-21 Board Of Trustees Of The Leland Stanford Junior University Norwalk virus human gastroenteritis agent and molecular cloning of corresponding cdnas
JPH07509122A (ja) 1992-04-08 1995-10-12 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ,アズ レプリゼンテッド バイ ザ セクレター,デパートメント オブ ヘルス アンド ヒューマン サービシーズ 野生型麻疹ウイルス糖タンパク質:ワクチンおよびその検出方法
WO1994005700A2 (en) 1992-09-07 1994-03-17 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
CA2189882C (en) 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
EE9900612A (et) 1997-04-08 2000-08-15 Merck & Co., Inc. Inimese papilloomiviiruse stabiliseeritud preparaadid
JP2002508748A (ja) 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
EA200100236A1 (ru) 1998-08-14 2001-08-27 Мерк Энд Ко., Инк. Способ очистки вирусных частиц, подобных вирусу папилломы человека
ATE323508T1 (de) 1998-12-17 2006-05-15 Merck & Co Inc Synthetische virus-ähnliche partikel mit heterologen epitopen.
ES2313881T3 (es) * 1999-02-05 2009-03-16 MERCK & CO., INC. Formulaciones de vacunas frente al papilomavirus humano.
US7067638B1 (en) 1999-06-22 2006-06-27 Japan As Represented By Director-General National Institute Of Infectious Diseases Small round structured virus (SRSV) detection kit
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス(nv)を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2003213060A1 (en) 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
ATE521367T1 (de) 2002-06-07 2011-09-15 Kentucky Bioproc Llc Flexlibler aufbau- und darreichungs-plattform von impfstoffen
DE60335186D1 (de) 2002-06-20 2011-01-13 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
US20050106178A1 (en) 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
EP1599188A2 (en) 2003-02-20 2005-11-30 Becton, Dickinson and Company POWDER FORMULATIONS OF RECOMBINANT STAPHYLOCOCCAL, ENTEROTOXIN B (<SB>R</SB>SEB) MADE BY ATMOSPHERIC SPRAY-FREEZE DRYING FOR IMPROVED VACCINATION
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
EP1670824A2 (en) 2003-09-24 2006-06-21 Montana State University Norovirus monoclonal antibodies and peptides
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP1846028A4 (en) 2005-01-05 2010-06-30 Philadelphia Health & Educatio TRANSPORT, BIOACTIVE SUBSTANCES AND VIRAL VACCINES
EP1846439A2 (en) 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
US7767212B2 (en) 2005-03-18 2010-08-03 Cytos Biotechnology Ag CAT allergen conjugates and uses thereof
EP1885394A4 (en) 2005-06-01 2009-10-21 Dow Global Technologies Inc PRODUCTION OF MULTIVALENT PARTICLES LIKE VIRUSES
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスgiの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
EP2601970B1 (en) 2006-09-29 2016-10-26 Takeda Vaccines, Inc. Norovirus vaccine formulations
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
KR101576219B1 (ko) * 2007-03-14 2015-12-10 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
US8648229B2 (en) 2007-09-12 2014-02-11 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
SG2013057732A (en) 2008-08-08 2015-02-27 Ligocyte Pharmaceuticals Inc Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
AU2009338516A1 (en) * 2009-01-22 2011-08-18 Pharmathene, Inc. Stable vaccine compositions and methods of use
ES2552383T3 (es) * 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
AU2011207355B2 (en) 2010-01-21 2015-04-02 Takeda Vaccines, Inc. Targeted heterologous antigen presentation on Calicivirus virus-like particles
CA2798323A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
BR112014000656A2 (pt) 2011-07-11 2017-02-14 Takeda Vaccines Inc formulações de vacina parenteral contra norovírus
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CA3008289C (en) 2015-12-16 2023-10-31 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
CA3099342A1 (en) 2018-05-03 2019-11-07 Board Of Regents, The University Of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
US20210308249A1 (en) 2018-08-20 2021-10-07 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
EP3924467A1 (en) 2019-02-15 2021-12-22 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy

Similar Documents

Publication Publication Date Title
JP2014520852A5 (cg-RX-API-DMAC7.html)
Brocato et al. Progress on the prevention and treatment of hantavirus disease
JP2011225578A5 (cg-RX-API-DMAC7.html)
Rajao et al. Pathogenesis and vaccination of influenza A virus in swine
JP2017537066A5 (cg-RX-API-DMAC7.html)
JP2013534248A5 (cg-RX-API-DMAC7.html)
JP2014051497A5 (cg-RX-API-DMAC7.html)
JP2010522208A5 (cg-RX-API-DMAC7.html)
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
JP2013216685A5 (cg-RX-API-DMAC7.html)
JP2011504486A5 (cg-RX-API-DMAC7.html)
Rajão et al. Influenza A virus hemagglutinin protein subunit vaccine elicits vaccine-associated enhanced respiratory disease in pigs
Ibanez et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A
JP2010529999A5 (cg-RX-API-DMAC7.html)
JP2013537518A5 (cg-RX-API-DMAC7.html)
JP2014518841A5 (cg-RX-API-DMAC7.html)
JP2011246469A5 (cg-RX-API-DMAC7.html)
JP2012184234A5 (cg-RX-API-DMAC7.html)
JP2013518107A5 (cg-RX-API-DMAC7.html)
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
JP2013531679A5 (cg-RX-API-DMAC7.html)
JP2013519645A5 (cg-RX-API-DMAC7.html)
JP2011105739A5 (cg-RX-API-DMAC7.html)
JP2008533007A5 (cg-RX-API-DMAC7.html)
JP2012519182A5 (cg-RX-API-DMAC7.html)